Breast Cancer

Over a million women worldwide are diagnosed with breast cancer annually. Alongside surgery, radiotherapy and immunotherapy, pharmaceutical products (including hormonal therapy and chemotherapy) are in the frontline against this terrible disease. Market reports in this section enable buyers to read up on the latest breast cancer drug pipelines and R&D strategies, as well as the medical and commercial activities of major players and niche operators such Abraxis Bioscience, Aeterna Zentaris, Agendia BV, Aphton Corp, Array BioPharma, AstraZeneca Plc, Bristol Myers Squibb, Dendreon Corporation, Eli Lilly, Genentech, Genta, Novartis AG, Pfizer, Roche Group, Sanofi-Aventis, Schering AG, Therion Biologics, and ViRexx Medical. Also included are cutting edge academic journals and various expert textbooks for medical professionals involved in breast cancer treatment. Show Less ... more

• Optimizing Treatments for ER/PR Positive HER2/neu Negative Metastatic Breast Cancer: US Oncologist Survey

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 The Assessment Group, Jan 2011 , Pages: 31
  Patient specific case scenarios that unfold throughout the report, presented to 174 high-prescribing oncologists on ER/PR Positive HER2neu Negative Metastatic Breast Cancer for their open responses...

• US Oncologist Survey: Optimizing Treatment for Metastatic Breast Cancer

  EURO€ 922.00USD$ 1,200.00GBP£ 776.00AUD$ 1,174.00JPY¥ 118,480.00SEK 7 879,00CHF 1'131.00CAD$ 1,223.00 The Assessment Group, Jan 2011 , Pages: 59
  Treatment choices of 174 high-prescribing oncologists in response to clinical patient scenarios Provides rich insights into specific treatment decisions, factors influencing their decisions, barriers...

• Biomarkers in Breast Cancer - 2011

  EURO€ 1,771.00USD$ 2,304.00GBP£ 1,490.00AUD$ 2,254.00JPY¥ 227,484.00SEK 15 128,00CHF 2'172.00CAD$ 2,348.00 BioPharm Reports (VennBio Ltd.), Jan 2011 , Pages: 195
  This report provides a comprehensive and up-to-date review of breast cancer biomarkers Recent years have seen the discovery of significant numbers of new biomarkers and clinical data are now available...

• Pipeline Insight: Cancer Overview – Breast and Gynecological Cancers

  EURO€ 11,684.00USD$ 15,200.00GBP£ 9,830.00AUD$ 14,867.00JPY¥ 1,500,741.00SEK 99 801,00CHF 14'327.00CAD$ 15,488.00 Datamonitor, Dec 2010
  The "Pipeline Insight: Cancer Overview – Breast and Gynecological Cancers" report is due to be published in December 2010 This report will cover the following key topics: - Pipeline Overview and Dynamics...

• Stakeholder Insight: Breast Cancer (Hormone Receptor-Negative)

  EURO€ 11,684.00USD$ 15,200.00GBP£ 9,830.00AUD$ 14,867.00JPY¥ 1,500,741.00SEK 99 801,00CHF 14'327.00CAD$ 15,488.00 Datamonitor, Nov 2010 , Pages: 276
  Triple-negative breast cancer offers a significant opportunity to new market entrants while Herceptin dominates the HER-2-positive market While some triple-negative breast cancer (TNBC) patients now...

• The Top 30 Developers of Molecular Diagnostic Tests for Breast Cancer

  EURO€ 195.00USD$ 254.00GBP£ 164.00AUD$ 248.00JPY¥ 25,047.00SEK 1 666,00CHF 239.00CAD$ 259.00 Research Facts Ltd, Nov 2010 , Pages: 72
  According to the WHO’s International Agency for Research on Cancer’s most recent estimates, breast cancer is by far the most frequent cancer among women with an estimated 1 38 million new cancer cases...

• Global Breast Cancer Drugs market 2009-2013

  EURO€ 1,153.00USD$ 1,500.00GBP£ 970.00AUD$ 1,467.00JPY¥ 148,099.00SEK 9 849,00CHF 1'414.00CAD$ 1,528.00 Infiniti Research Limited, Jul 2010 , Pages: 22
  The cancer drugs represent a large potential on the therapeutic market Cancer is the second leading cause of death worldwide after cardiovascular diseases According to World Heath Organization (WHO),...

• Portfolio Analytics and Planning in the Breast Cancer Pipeline - Change is Around the Corner in a Highly Competitive Market Place

  EURO€ 1,950.00USD$ 2,537.00GBP£ 1,641.00AUD$ 2,481.00JPY¥ 250,475.00SEK 16 657,00CHF 2'391.00CAD$ 2,585.00 Bioseeker, Jun 2010 , Pages: 913
  This report comprises defined and up to date development strategies for 405 breast cancer drugs within the portfolio of 220 investigators, from Ceased to Marketed The report extensively analyses 207...

• Breast Imaging and Digital Mammography

  EURO€ 926.00USD$ 1,204.00GBP£ 779.00AUD$ 1,178.00JPY¥ 118,924.00SEK 7 909,00CHF 1'135.00CAD$ 1,227.00 CME Group, Mar 2010
  Breast Imaging and Digital Mammography provides a concentrated overview of the current status of breast imaging and recent developments in the subspecialty Emphasis on the application of mammographic...

• Thought Leader Insight & Analysis Report - Breast Cancer Q1 2010

  EURO€ 5,765.00USD$ 7,500.00GBP£ 4,850.00AUD$ 7,336.00JPY¥ 740,497.00SEK 49 244,00CHF 7'069.00CAD$ 7,642.00 Medpredict, Mar 2010 , Pages: 143
  In this report, the 24th in our Oncology series we summarize the perspectives of six world-class experts in the treatment of breast cancer In this report they provide their opinions on standards of...

• Pittsburgh Breast Imaging

  EURO€ 757.00USD$ 984.00GBP£ 637.00AUD$ 963.00JPY¥ 97,203.00SEK 6 464,00CHF 928.00CAD$ 1,003.00 CME Group, Oct 2009
  The Allegheny General Hospital recently conducted the Pittsburgh Breast Imaging course This nationally recognized annual seminar is offered for radiologists, surgeons, radiologists-in-training, mammography...

• Breast Disease Diagnosis and Therapy Markets: Europe and Asia-Pacific

  EURO€ 5,377.00USD$ 6,995.00GBP£ 4,524.00AUD$ 6,842.00JPY¥ 690,637.00SEK 45 928,00CHF 6'593.00CAD$ 7,128.00 Life Science Intelligence, Apr 2009 , Pages: 241
  The market for breast cancer detection, diagnosis, and treatment is well-developed in the U S and much of Europe It has remained relatively under-developed in the Asia-Pacific region, however, although...

• Chinese Markets for Breast Cancer Treatment Drugs

  EURO€ 2,140.00USD$ 2,000.00GBP£ 1,216.00AUD$ 2,912.00JPY¥ 245,413.00SEK 17 258,00CHF 2'872.00CAD$ 2,673.00 AMID Co, Feb 2009 , Pages: 220
  Chinas demand for Breast Cancer Treatment Drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines Chinas...

• Lynn Sage Breast Cancer Symposium

  EURO€ 634.00USD$ 825.00GBP£ 534.00AUD$ 807.00JPY¥ 81,455.00SEK 5 417,00CHF 778.00CAD$ 841.00 CME Group, Dec 2008
  Northwestern University, Feinberg School of Medicine The Robert H Lurie Comprehensive Cancer Center of Northwestern University recently conducted the Lynn Sage Breast Cancer Symposium The 10th Annual...

• Breast Cancer: An Atlas of Investigation and Management

  EURO€ 89.00USD$ 116.00GBP£ 75.00AUD$ 113.00JPY¥ 11,451.00SEK 761,00CHF 109.00CAD$ 118.00 Clinical Publishing, Sep 2008 , Pages: 128
  Meeting the needs of specialist surgeons, oncologists, radiologists, breast physicians and breast-care nurses, this atlas provides a comprehensive visual presentation of breast cancer Compiled by leading...

• Currently Druggable in Breast Cancer: A Drug Target Competitive Analysis

  EURO€ 1,950.00USD$ 2,537.00GBP£ 1,641.00AUD$ 2,481.00JPY¥ 250,475.00SEK 16 657,00CHF 2'391.00CAD$ 2,585.00 Bioseeker, Aug 2008 , Pages: 316
  This report aims to analyze the current and future potential of breast cancer pipeline by examining key fundamentals across the entire pipeline of drug candidates The author has identified three fundamental...

• Breast Cancer: An Overview

  EURO€ 25.00USD$ 33.00GBP£ 21.00AUD$ 32.00JPY¥ 3,211.00SEK 214,00CHF 31.00CAD$ 33.00 Focus Medica Pte Ltd, Jul 2008
  Breast cancer is the second largest cause of cancer related death in women. There are different forms of breastcancer and they are classified based on the stage of the tumor.This presentation describes...

• Key Opinion Leader Mapping. Breast Cancer: USA Landscape Analysis. Special Focus on KOLs of Tomorrow.

  EURO€ 7,149.00USD$ 9,300.00GBP£ 6,014.00AUD$ 9,096.00JPY¥ 918,217.00SEK 61 062,00CHF 8'766.00CAD$ 9,477.00 FAS Research, May 2008 , Pages: 68
  Pharma’s appetite for KOLs is growing This report provides the names and affiliated institutions of the most influential Key Opinion Leaders in the US Breast Cancer Market and shows how they are connected...

• U.S. Breast Cancer Therapeutics Markets

  EURO€ 4,612.00USD$ 6,000.00GBP£ 3,880.00AUD$ 5,868.00JPY¥ 592,398.00SEK 39 395,00CHF 5'655.00CAD$ 6,114.00 Frost & Sullivan, Mar 2008 , Pages: 78
  This report analyzes the U S breast cancer therapeutics market, for the forecast period 2000 to 2010 The report is segmented into 5 chapters viz Executive Summary, Total Market, Cytotoxic Therapeutics...

• NANO Magazine - Issue 5

  EURO€ 12.00USD$ 15.00GBP£ 10.00AUD$ 15.00JPY¥ 1,527.00SEK 102,00CHF 15.00CAD$ 16.00 NANO Magazine, Jan 2008 , Pages: 44
  This issue of NANO cancer. We examine advances in nanotechnology from diagnosis and imaging to drug delivery and therapy that could provide real solutions to finally overcoming devastating disease. Ancient...

• Antibody Drug Targets and Focus on Breast & Prostate Cancer

  EURO€ 3,450.00USD$ 4,488.00GBP£ 2,903.00AUD$ 4,390.00JPY¥ 443,148.00SEK 29 470,00CHF 4'230.00CAD$ 4,574.00 Bioseeker, Nov 2007 , Pages: 380
  In this triple analysis report we have analyzed three major and intertwined areas of cancer R&D, Antibody drug target, Breast- and Prostate cancer, which are all subjects to an extensive number of innovative...

• U.S. Breast Disease Diagnosis and Therapy Markets

  EURO€ 2,998.00USD$ 3,900.00GBP£ 2,522.00AUD$ 3,814.00JPY¥ 385,059.00SEK 25 607,00CHF 3'676.00CAD$ 3,974.00 Life Science Intelligence, Aug 2007 , Pages: 244
  The breast disease diagnosis and therapy markets are poised for substantial and sustainable growth, according to this new report The report, Breast Disease Diagnosis and Therapy Markets, 2007, finds...

• Prostate and Breast Cancer- New Treatments & Developmental Progress

  EURO€ 2,360.00USD$ 3,070.00GBP£ 1,986.00AUD$ 3,003.00JPY¥ 303,139.00SEK 20 159,00CHF 2'894.00CAD$ 3,129.00 Bioseeker, Mar 2007 , Pages: 192
  Introduction The treatment for breast and prostate cancer are under intense progress Cancer of the prostate is the second most frequently diagnosed cancer in men in the US and approximately 3 million...

• Breast Cancer - Therapeutic And Competitive Insights

  EURO€ 1,560.00USD$ 2,030.00GBP£ 1,312.00AUD$ 1,985.00JPY¥ 200,380.00SEK 13 325,00CHF 1'913.00CAD$ 2,068.00 Bioseeker, Feb 2007 , Pages: 107
  Introduction Overall approximately 3 million women in the US are living with breast cancer But, even with an increasing incidence, the mortality rate has dropped slightly during the last 10-15 years...

• Breast Cancer Therapeutics - Global Strategic Business Report

  EURO€ 3,496.00USD$ 3,950.00GBP£ 2,330.00AUD$ 5,462.00JPY¥ 473,679.00SEK 31 073,00CHF 5'202.00CAD$ 5,066.00 Global Industry Analysts, Inc, Oct 2006 , Pages: 563
  This report analyzes the worldwide markets for Breast Cancer Therapeutics in US$ Million The major product segments analyzed are Hormonal Therapy, Chemotherapy, and Innovative Therapy The report provides...

• Drug Targets for Breast Cancer

  EURO€ 1,302.00USD$ 1,693.00GBP£ 1,095.00AUD$ 1,656.00JPY¥ 167,178.00SEK 11 118,00CHF 1'596.00CAD$ 1,725.00 Informa Healthcare, Jan 2006 , Pages: 170
  Breast cancer is a complex heterogeneous disease characterised by uncontrolled growth and spread of abnormal cells. It is also very prevalent, with reports from the World Health Organization estimating...

• Strategic Analysis of the Global Breast Cancer Therapeutics Pipeline

  EURO€ 3,805.00USD$ 4,950.00GBP£ 3,201.00AUD$ 4,841.00JPY¥ 488,728.00SEK 32 501,00CHF 4'666.00CAD$ 5,044.00 Frost & Sullivan, Jun 2004
  Generic competition and impending patent expirations threaten to curb the spectacular growth witnessed by the breast cancer market in recent years. In a bid to boost revenue generation, pharmaceutical...